Background: The success of personalized medicine depends on factors influencing the availability and implementation of its new tools to individualize clinical care. However, little is known about physicians' views of the availability of personalized medicine across racial/ethnic groups and the relationship between perceived availability and clinical implementation. This study examines physicians' perceptions of key elements/tools and potential barriers to personalized medicine in connection with their perceptions of the availability of the latter across subpopulations. Methods: Study subjects consisted of physicians recruited from Cincinnati Children's Hospital Medical Center and UC Health. An electronic survey conducted from September 2012 to November 2012 recruited 104 physicians. Wilcoxon rank sum analysis compared groups. Results: Physicians were divided about whether personalized medicine contributes to health equality, as 37.4% of them believe that personalized medicine is currently available only for some subpopulations. They also rated the importance of racial/ethnic background almost as high as the importance of genetic information in the delivery of personalized medicine. Actual elements of personalized medicine rated highest include family history, drug-drug interaction alerts in medical records, and biomarker measurements to guide therapy. Costs of gene-based therapies and genetic testing were rated the most significant barriers. The ratings of several elements and barriers were associated with perceived availability of personalized medicine across subpopulations. Conclusion: While physicians hold differing views about the availability and implementation of personalized medicine, they likewise establish complex relationships between race/ethnicity and personalized medicine that may carry serious implications for its clinical success.

Keywords:
Genetic testing, Health equality, Individualized healthcare, Perceptions, Personalized medicine, Pharmacogenomics, Race
1.
Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, Mountain JL, Perez-Stable EJ, Sheppard D, Risch N: The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003;348:1170-1175.
2.
Maglo KN: Group-based and personalized case in an age of genomic and evidence-based medicine: a reappraisal. Perspect Biol Med 2012;55:137-154.
3.
Ramos E, Callier SL, Rotimi CN: Why personalized medicine will fail if we stay the course. Per Med 2012;9:839-847.
4.
Burke W, Psaty BM: Personalized medicine in the era of genomics. JAMA 2007;298:1682-1684.
5.
Meyer UA, Zanger UM, Schwab M: Omics and drug response. Pharmacol Toxicol 2013;53:475-503.
6.
NCI: Dictionary of Cancer Terms; National Institutes of Health, 2012, http://www.cancer.gov/dictionary?cdrid=561717
7.
Need AC, Goldstein DB: Next generation disparities in human genomics: concerns and remedies. Trends Genet 2009;25:489-494.
8.
Kittles R: Genes and environments: moving toward personalized medicine in the context of health disparities. Ethn Dis 2012;22:S1-43-46.
9.
Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG, Bradman N, Goldstein DB: Population genetic structure of variable drug response. Nat Genet 2001;29:265-269.
10.
Veeramah KR, Thomas MG, Weale ME, Zeitlyn D, Tarekegn A, Bekele E, Mendell NR, Shephard EA, Bradman N, Phillips IR: The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-saharan africa. Pharmacogenet Genomics 2008;18:877-886.
11.
Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG: Cyp1a2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics 2010;20:647-664.
12.
Horsfall LJ, Zeitlyn D, Tarekegn A, Bekele E, Thomas MG, Bradman N, Swallow DM: Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet 2011;75:236-246.
13.
Bains RK, Kovacevic M, Plaster CA, Tarekegn A, Bekele E, Bradman NN, Thomas MG: Molecular diversity and population structure at the cytochrome p450 3A5 gene in Africa. BMC Genet 2013;14:34.
14.
Maglo KN, Martin LJ: Researching vs. reifying race: the case of obesity research. Humanamente 2012;22:111-143.
15.
Beauchamp TL, Childress JF: Principles of Biomedical Ethics, ed 6. New York, Oxford University Press, 2009.
16.
Maiti S, Kumar KH, Castellani CA, O'Reilly R, Singh SM: Ontogenetic de novo copy number variations (CNVs) as a source of genetic individuality: Studies on two families with MZD twins for schizophrenia. PLoS One 2011;6:e17125.
17.
Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S, Diaz de Stahl T, Menzel U, Sandgren J, von Tell D, Poplawski A, Crowley M, Crasto C, Partridge EC, Tiwari H, Allison DB, Komorowski J, van Ommen GJ, Boomsma DI, Pedersen NL, den Dunnen JT, Wirdefeldt K, Dumanski JP: Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet 2008;82:763-771.
18.
Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE: The predictive capacity of personal genome sequencing. Sci Transl Med 2012;4:133ra58.
19.
Rotimi CN, Jorde LB: Ancestry and disease in the age of genomic medicine. N Engl J Med 2010;363:1551-1558.
20.
Haga SB, Carrig MM, O'Daniel JM, Orlando LA, Killeya-Jones LA, Ginsburg GS, Cho A: Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling. J Gen Intern Med 2011;26:834-840.
21.
Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD: Personalised medicine in canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 2011;1:e000110.
22.
Najafzadeh M, Davis JC, Joshi P, Marra C: Barriers for integrating personalized medicine into clinical practice: a qualitative analysis. Am J Med Genet A 2013;161:758-763.
23.
White C, Meurnier J: Cogent syndicated genetic attitudes & trends survey. Cogent Research, 2003.
24.
PMC: The case for personalized medicine. Personalized Medicine Coalition, 2006. http://www.personalizedmedicinecoalition.org/.
25.
PMC: The case for personalized medicine. Personalized Medicine Coalition, 2011. http://www.personalizedmedicinecoalition.org/sites/default/files/files/Case_for_PM_3rd_edition.pdf.
26.
Report C: Medications for the masses? Pharmacogenomics is an important public health issue; CDC, 2011. http://blogs.cdc.gov/genomics/2011/07/21/.
27.
Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M: Genome-wide association studies in diverse populations. Nat Rev Genet 2010;11:356-366.
28.
Ferdinand K, Ferdinand D: Cardiovascular disease disparities: racial/ethnic factors and potential solutions. Curr Cardiovasc Risk Rep 2009;3:187-193.
29.
Bibbins-Domingo K, Fernandez A: BiDil for heart failure in black patients: Implications of the U.S. Food and Drug Administration approval. Ann Intern Med 2007;146:52-56.
30.
Lesko LJ: Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007;81:807-816.
31.
Wang L, McLeod HL, Weinshilboum RM: Genomics and drug response. N Engl J Med 2011;364:1144-1153.
32.
Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625-629.
33.
Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT: Influence of CYP2C9 and VKORC1 1173c/t genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008;83:312-321.
34.
Lam MP, Cheung BM: The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol 2012;73:340-347.
35.
Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ: The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011;89:408-415.
36.
Cavallari LH, Perera MA: The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol 2012;8:563-576.
37.
Perera MA, Cavallari LH, Limdi NA, et al: Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013;382:790-796.
38.
Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC: Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 2012;13:407-418.
39.
Hernandez W, Gamazon ER, Aquino-Michaels K, Patel S, O'Brien TJ, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, Douglas JN, Nicolae D, Cavallari LH, Perera MA: Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J 2013, E-pub ahead of print.
40.
Daniels N: Just Health: Meeting Health Needs Fairly. New York, Cambridge University Press, 2008.
41.
Powers M, Faden R: Social Justice: The Moral Foundations of Public Health and Health Policy. Oxford, Oxford University Press, 2006.
42.
Chan IS, Ginsburg GS: Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 2011;12:217-244.
43.
Walter FM, Emery J: Perceptions of family history across common diseases: a qualitative study in primary care. Fam Pract 2006;23:472-480.
44.
Fuller M, Myers M, Webb T, Tabangin M, Prows C: Primary care providers' responses to patient-generated family history. J Genet Couns 2010;19:84-96.
45.
Ko Y, Abarca J, Malone DC, Dare DC, Geraets D, Houranieh A, Jones WN, Nichol WP, Schepers GP, Wilhardt M: Practitioners' views on computerized drug-drug interaction alerts in the VA system. J Am Med Inform Assoc 2007;14:56-64.
46.
Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC, Jr., Zhang Z, Nicoletto MO: Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 2010;31:209-215.
47.
Galasko D, Montine TJ: Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 2010;4:27-36.
48.
Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, Hasin Y, Biasucci LM, Giannitsis E, Lindahl B, Koenig W, Tubaro M, Collinson P, Katus H, Galvani M, Venge P, Alpert JS, Hamm C, Jaffe AS: Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the study group on biomarkers in cardiology of the ESC working group on acute cardiac care. Eur Heart J 2012;33:2001-2006.
49.
Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23:276-292.
50.
Fackler JL, McGuire AL: Paving the way to personalized genomic medicine: steps to successful implementation. Curr Pharmacogenomics Person Med 2009;7:125.
51.
Dodson C: Knowledge and attitudes concerning pharmacogenomics among healthcare professionals. Pers Med 2011;8:421-428.
52.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med 2004;350:2129-2139.
53.
Sermet-Gaudelus I: Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev 2013;22:66-71.
55.
Wang Y, Kennedy J, Caggana M, Zimmerman R, Thomas S, Berninger J, Harris K, Green NS, Oyeku S, Hulihan M, Grant AM, Grosse SD: Sickle cell disease incidence among newborns in New York state by maternal race/ethnicity and nativity. Genet Med 2013;15:222-228.
56.
Brody H, Hunt LM: BiDil: assessing a race-based pharmaceutical. Ann Fam Med 2006;4:556-560.
57.
Cooper RS, Kaufman JS, Ward R: Race and genomics. N Engl J Med 2003;348:1166-1170.
58.
Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB: Carrier screening for beta-thalassemia: a review of international practice. Eur J Hum Genet 2010;18:1077-1083.
59.
USFDA: Table of Pharmacogenomic Biomarkers in Drug Labels, 2013. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
60.
Aihara M: Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol 2011;38:246-254.
61.
Hamburg MA, Collins FS: The path to personalized medicine. N Engl J Med 2010;363:301-304.
62.
Meckley LM, Neumann PJ: Personalized medicine: factors influencing reimbursement. Health Policy 2010;94:91-100.
63.
PharmGKB: CPIC: Clinical pharmacogenetics implementation consortium; Stanford University, 2001-2013, 2013. http://www.pharmgkb.org/page/cpic.
64.
SACGHS: U.S. System of oversight of genetic testing, 2008. http://osp.od.nih.gov/sites/default/files/SACGHS_oversight_report.pdf.
65.
UnitedHealth: Personalized medicine: Trends and prospects for the new science of genetic testing and molecular diagnostics. Minnetonka, MN, UnitedHealth Center for Health Reform and Modernization, 2012. http://osp.od.nih.gov/sites/default/files/SACGHS_oversight_report.pdf.
66.
NIH: Genetic Information Nondiscrimination Act (GINA) of 2008. http://www.genome.gov/24519851.
67.
Genetic information nondiscrimination act; Genetic Alliance, Genetics and Public Policy Center, National Coalition for Health Professional Education in Genetics. http://ginahelp.org/.
68.
Tambuyzer E: Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010;9:921-929.
69.
Cox TM: Gaucher disease: clinical profile and therapeutic developments. Biologics 2010;4:299-313.
70.
Li C: Personalized medicine - the promised land: are we there yet? Clin Genet 2011;79:403-412.
71.
Bonetta L: Whole-genome sequencing breaks the cost barrier. Cell 2010;141:917-919.
72.
Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-293.
73.
Akinniyi DC, Payne PW: BiDil lessons: cardiologists views of a race-based personalized medicine. J Am Coll Cardiol 2011;57:E1926-E1926.
74.
Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.
75.
Collins FS: What we do and don't know about ‘race', ‘ethnicity', genetics and health at the dawn of the genome era. Nat Genet 2004;36:S13-S15.
76.
Bloche MG: Race-based therapeutics. N Engl J Med 2004;351:2035-2037.
77.
Kahn J: Mandating race: how the USPTO is forcing race into biotech patents. Nat Biotechnol 2011;29:401-403.
78.
Frank D, Gallagher TH, Sellers SL, Cooper LA, Price EG, Odunlami AO, Bonham VL: Primary care physicians' attitudes regarding race-based therapies. J Gen Intern Med 2010;25:384-389.
79.
Royal CD, Novembre J, Fullerton SM, Goldstein DB, Long JC, Bamshad MJ, Clark AG: Inferring genetic ancestry: opportunities, challenges, and implications. Am J Hum Genet 2010;86:661-673.
80.
Nulty DD: The adequacy of response rates to online and paper surveys: what can be done? Assess Eval High Educ 2008;33:301-314.
81.
Leece P, Bhandari M, Sprague S, Swiontkowski MF, Schemitsch EH, Tornetta P, Devereaux PJ, Guyatt GH: Internet versus mailed questionnaires: a randomized comparison (2). J Med Internet Res 2004;6:e30.
82.
Dillman DA: Mail and Internet Surveys: The Tailored Design Method. Hoboken, New Jersey, Wiley, 2007
83.
VanGeest JB, Johnson TP, Welch VL: Methodologies for improving response rates in surveys of physicians: a systematic review. Eval Health Prof 2007;30:303-321.
84.
Flanigan TS, McFarlane E, Cook S: Conducting survey research among physicians and other medical professionals - a review of current literature. ASA Proceedings of the Section on Survey Research Methods 2008:4136-4147.
85.
McFarlane E, Olmsted MG, Murphy J, Hill CA: Nonresponse bias in a mail survey of physicians. Eval Health Prof 2007;30:170-185.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.